ஐ.எஸ்.எஸ்.என்: 2472-4971
Tomoko Yamazaki, Noriyuki Koyama, Takeshi Okanoue and Toru Miyazaki
The number of patients in Non-alcoholic Steatohepatitis (NASH) and its associated Hepato Cellular Carcinoma (HCC) is increasing rapidly along with the change of lifestyle. So far, however, no diagnostic tools specifically use for NASH-associated HCC have not been established yet. Recently, we have reported circulating levels of activated Apoptosis Inhibitor of Macrophage (AIM, also called CD5L) can be a sensitive and specific biomarker to diagnose NASH-associated HCC in human. In addition, we demonstrated that AIM facilitated the diminishment of HCC tumors in mice. In this report, we discuss about the benefits of application of AIM as future diagnostic and therapeutic tools against NASH-associated HCC.